Literature DB >> 23908540

Cardiovascular comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting.

April W Armstrong1, Joel M Gelfand, Wolf-Henning Boehncke, Ehrin J Armstrong.   

Abstract

At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Stockholm, Sweden, several GRAPPA members led a panel discussion on cardiovascular (CV) comorbidities of psoriasis and psoriatic arthritis (PsA). The panelists discussed the role of insulin resistance in the pathophysiology of psoriasis, the possible effect of tumor necrosis factor inhibitors on CV comorbidities, and the effect of 12/23 monoclonal antibodies on CV outcomes. The panelists also addressed how lessons from CV comorbidity research could be applied to other areas of comorbidity research in psoriasis and PsA and identified future research directions in this area.

Entities:  

Keywords:  BIOLOGICS; CARDIOVASCULAR COMORBIDITIES; COMPARATIVE EFFECTIVENESS; PSORIASIS; PSORIATIC ARTHRITIS; TUMOR NECROSIS FACTOR INHIBITORS

Mesh：

Substances：

Year:  2013        PMID： 23908540     DOI： 10.3899/jrheum.130457

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


  8 in total

1.  Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis.

Authors:  Alexander V Sorokin; Kazuhiko Kotani; Youssef A Elnabawi; Amit K Dey; Aparna P Sajja; Shingo Yamada; Masashi Ueda; Charlotte L Harrington; Yvonne Baumer; Justin A Rodante; Joel M Gelfand; Marcus Y Chen; Aditya A Joshi; Martin P Playford; Alan T Remaley; Nehal N Mehta
Journal:  Circ Res       Date:  2018-11-09       Impact factor: 17.367

2.  Addressing comorbidities in psoriatic disease.

Authors:  Priya Patel; Cheryl F Rosen; Vinod Chandran; Yang Justine Ye; Dafna D Gladman
Journal:  Rheumatol Int       Date:  2017-11-28       Impact factor: 2.631

Review 3.  In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.

Authors:  Sarah A R Siegel; Kevin L Winthrop
Journal:  Curr Rheumatol Rep       Date:  2019-06-06       Impact factor: 4.592

Review 4.  Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?

Authors:  Philippa D K Curry; Andrew P Morris; Anne Barton; James Bluett
Journal:  Pharmacogenomics J       Date:  2022-10-15       Impact factor: 3.245

Review 5.  Potential Immunological Links Between Psoriasis and Cardiovascular Disease.

Authors:  Aparna P Sajja; Aditya A Joshi; Heather L Teague; Amit K Dey; Nehal N Mehta
Journal:  Front Immunol       Date:  2018-06-01       Impact factor: 7.561

6.  Cardiovascular risk evaluation through heart rate variability analysis in psoriatic patients before and after 24 weeks of etanercept therapy: Prospective study.

Authors:  Concetta Potenza; Gianfranco Raimondi; Riccardo Pampena; Ilaria Proietti; Giorgio La Viola; Nicoletta Bernardini; Ersilia Tolino; Sara Zuber; Veronica Balduzzi; Beatrice Scordamaglia; Nevena Skroza
Journal:  J Int Med Res       Date:  2016-09       Impact factor: 1.671

7.  First-in-man intravenous implantation of stromal vascular fraction in psoriasis: a case study.

Authors:  Kristin Comella; Michelle Parlo; Rosemary Daly; Kellie Dominessy
Journal:  Int Med Case Rep J       Date:  2018-03-21

8.  Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy.

Authors:  Shinichi Imafuku; Min Zheng; Yayoi Tada; Xibao Zhang; Colin Theng; Suganthi Thevarajah; Yi Zhao; Hae Jun Song
Journal:  J Dermatol       Date:  2018-05-09       Impact factor: 4.005
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.